The Medical Letter on Drugs and Therapeutics
Fenofibric Acid (Trilipix)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of fenofibric acid (Trilipix – Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor (statin) who have, or have risk factors for, coronary heart disease. It is the first fibrate approved by the FDA specifically for combined use with a statin. Trilipix is also approved as monotherapy for hypertriglyceridemia, hypercholesterolemia and low HDL-C. The patent for Tricor, Abbott’s older formulation of fenofibrate, will expire in 2011.

FENOFIBRATES — Fenofibrate is available in nonmicronized tablets and capsules that are poorly absorbed and usually must be taken with a meal, and in micronized capsules that are more reliably absorbed. Fenofibric acid is the active metabolite of fenofibrate. Trilipix is the active choline salt of fenofibric acid; it is available as a delayed-release ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fenofibric Acid (Trilipix)
Article code: 1311a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian